Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AD17002 in Poorly Controlled Eosinophilic Asthma
NCT05985694Phase 2Completed
- Sponsor
- Advagene Biopharma Co., Ltd.
- Start
- Nov 2023
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of AD-17002 in eosinophilic asthma (EA), sponsored by Advagene Biopharma Co., Ltd.. Started Nov 2023; status: completed.
02
Drugs
AD-17002
03
Conditions
eosinophilic asthma (EA)
Beyond the preview
Go deeper on NCT05985694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05985694.